Skip to main content

Table 2 Study characteristics

From: Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease

Cohort

Number of Events

Number of patients

Person years

Mean age, years

Men, %

Mean FEV1%pred.

Mean mMRC

Past exacerbators, %

Mean no. prev. exacerbations

Current smoker, %

Mean BMI

Mean 6MWT, m

Mean SGRQ

Mean CAT

COPDgene

337

4484

10,603

63 (9)

56

57.4 (22.8)

1.5

0.16

 

43

27.9 (6.1)

376.1 (124.1)

36.9 (22.9)

 

Sevillaa

205

596

1562

66 (10)

95

43.5 (13.3)

1

0.25

1.16

24

29.2 (5.7)

   

Copenhagenb

186

2287

6618

61 (9)

54

70.5 (23.7)

1.3

  

71

25 (4.2)

   

Genkols

126

954

2708

65 (10)

61

46.9 (17)

1.3

0.15

0.6

47

25.4 (5)

   

Zaragoza IIa

118

1150

3069

63 (9)

93

62.3 (20.3)

1.1

0.17

0.91

34

27.5 (4.8)

356.2 (153.7)

  

HUNT

116

1571

4583

63 (13)

62

63.8 (18.7)

1.3

  

47

26.4 (4.4)

   

Galdakaoa

92

543

1497

68 (8)

96

55 (13.3)

0.9

0

0.65

21

28.3 (4.4)

408.9 (92.4)

  

Barmelweidb

79

232

555

72 (9)

60

45.2 (16.1)

1.1

  

21

26 (6.3)

363.4 (126.8)

  

Terrassa IIIa

78

181

423

72 (10)

95

45.2 (14.4)

1.2

0.31

1.28

23

27.9 (5)

330.4 (105.8)

  

Initiatives BPCO

76

930

1525

64 (10)

77

52.4 (20.3)

1.1

0.4

1.65

28

25.4 (5.5)

387.4 (120.8)

43.9 (19)

 

Terrassa Ia

72

135

284

72 (9)

92

41.3 (13)

1.3

0.25

1.03

17

26.3 (4.9)

   

SEPOCb

61

318

871

65 (9)

100

45 (18.3)

1.5

  

38

26.4 (4.2)

   

Requena IIa,c

52

186

396

71 (9)

99

44.5 (16.5)

1

0.16

0.62

17

28.1 (5.2)

380.1 (111.9)

  

ICE COLD ERIC

47

400

1071

67 (10)

57

55.3 (16.5)

1.5

0.13

0.58

39

26.1 (5.2)

   

PAC-COPDb

41

342

980

68 (9)

93

52.4 (16.2)

1

0.04

 

33

28.2 (4.7)

435.5 (90.6)

  

Tenerifea

34

275

653

63 (10)

79

55.8 (21.2)

1.2

0.06

0.37

42

27.3 (5.1)

487.4 (87.5)

  

Terrassa IIa

28

66

145

72 (9)

98

30.2 (12.9)

1

0.42

1.81

14

25.7 (4.3)

217.7 (76.6)

  

Requena Ia

23

174

393

72 (9)

99

48.1 (16.8)

1.2c

0.03

0.22

23

28 (4.2)

434.4 (125.3)

  

Zaragoza Ia

21

137

379

66 (8)

99

49.8 (17.6)

1.1

  

27

27.7 (4.6)

449 (91.9)

  

Son Espases Mallorca

17

115

292

70 (7)

79

41.5 (13.4)

1

0.59

 

27

27.1 (5.9)

401.5 (89.7)

 

16.6 (8.2)

Basqueb

16

106

299

71 (9)

98

46.9 (11.4)

0.6

  

23

26.1 (4.9)

442.9 (95.4)

  

Japan

15

147

409

69 (7)

100

47.1 (17.5)

0.9

  

22

21 (2.9)

 

36.6 (16.5)

 

La Princesa Madrid

11

318

633

71 (10)

74

50 (19.8)

1.1

0.18

0.77

19

26.2 (5.1)

337.1 (92.8)

  

Pamplonaa

7

190

470

65 (8)

84

68.9 (19.9)

1.1

  

37

27 (4.4)

463.2 (113.9)

  

Mar de Plata Argentina

3

99

147

64 (9)

60

48.8 (18.6)

1

0.29

 

21

27 (5.6)

353.2 (128.7)

 

16.1 (7.8)

A1ATDd

0

308

834

58 (10)

60

53.1 (25.1)

1.2

0.52

 

5

25.7 (4.9)

 

50.8 (19.9)

20.5 (8.1)

  1. Abbreviations: FEV1% pred. forced expiratory volume in 1 s percentage predicted, mMRC modified Medical Research Council (MMRC) dyspnea scale; past exacerbators are defined as patients with more than one exacerbation in the previous year; mean number previous exacerbations are referred to the previous year, BMI body mass index, 6MWT 6-min walk test, SGRQ Saint George’s Respiratory Questionnaire, CAT COPD Assessment Test
  2. The cohorts are presented in decreasing order of number of events. Most of the variables available provided by the 3CIA collaboration for the different cohorts are shown. In particular, we show all the variables constituting the scores analyzed in our study. We present the standard deviation for all individual variables whose distribution is approximately normal; this is not the case for count (with small numbers) or categorical variables, like number of previous exacerbations or mMRC)
  3. aCohorts belonging to the Collaborative Cohorts to Assess Multicomponent Indices of COPD in Spain (COCOMICS) collaboration
  4. bCohorts belonging to the ADO collaboration. For information concerning the cohorts, see [49]
  5. cSince none of the scores could be evaluated in the cohort Requena I (mainly because the variable dyspnoea was missing for 95% of the patients, i.e., for 165 out of 174 patients), this cohort was excluded from the analysis
  6. dSince there was no event in a follow-up of 3 years, the cohort A1ATD was excluded from the analysis
  7. Missing cells correspond to variables that are completely missing in the cohort of the correspondent row
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us